Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00404248 · ClinicalTrials.gov registry record · Phase 1

Tetra-O-Methyl Nordihydroguaiaretic Acid in Treating Patients With Recurrent High-Grade Glioma

A Phase 1 study of Brain and Central Nervous System Tumors, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

Completed
Registry status
Phase 1
Development phase
35
Enrollment target
9
Study locations

NCT00404248 is a Phase 1 study of Brain and Central Nervous System Tumors that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 35 participants, below the 183-participant average among 45 other Brain and Central Nervous System Tumors trials with a reported enrollment target (81% lower). The trial reports 9 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00404248, a Phase 1 study of Brain and Central Nervous System Tumors, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

COMPLETED
Registry status
Phase 1
Development phase
35 participants
Enrollment target
9
Study locations

Study Summary

RATIONALE: Drugs used in chemotherapy, such as tetra-O-methyl nordihydroguaiaretic acid (EM-1421), work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase I/II trial is studying the side effects and best dose of EM-1421 and to see how well it works in treating patients with recurrent high-grade glioma.

Conditions Studied

Brain and Central Nervous System Tumors

Interventions

  • OTHER pharmacological study
  • DRUG terameprocol

Study Locations (9)

Alabama

  • UAB Comprehensive Cancer Center - Birmingham

Florida

  • H. Lee Moffitt Cancer Center and Research Institute at University of South Florida - Tampa

Georgia

  • Winship Cancer Institute of Emory University - Atlanta

Maryland

  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins - Baltimore

Massachusetts

  • Massachusetts General Hospital - Boston

Michigan

  • Josephine Ford Cancer Center at Henry Ford Hospital - Detroit

North Carolina

  • Wake Forest University Comprehensive Cancer Center - Winston-Salem

Ohio

  • Cleveland Clinic Taussig Cancer Center - Cleveland

Trial Details

FieldValue
Enrollment Target 35 participants
Start Date 2007-01
Est. Completion 2012-02
Phase Phase 1

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

523 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00404248

The ClinicalTrials.gov registry entry for NCT00404248 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 183-participant average among 45 other Brain and Central Nervous System Tumors trials with a reported enrollment target (81% lower). The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Brain and Central Nervous System Tumors appearing as the primary indexed condition, and to 2 interventions - of which pharmacological study is the first listed.

NCT00404248 reports 9 study locations spanning 9 distinct geographic areas - top geographies include Alabama, Florida, Georgia.

Frequently Asked Questions

What is clinical trial NCT00404248 about?

NCT00404248 is a clinical study titled "Tetra-O-Methyl Nordihydroguaiaretic Acid in Treating Patients With Recurrent High-Grade Glioma". RATIONALE: Drugs used in chemotherapy, such as tetra-O-methyl nordihydroguaiaretic acid (EM-1421), work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase I/II trial is studying the side effects and best dose of EM...

What is the current status of trial NCT00404248?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2007-01. Estimated completion is 2012-02.

What conditions does trial NCT00404248 study?

This clinical trial studies the following conditions: Brain and Central Nervous System Tumors.

What interventions are being tested in trial NCT00404248?

The interventions under investigation include: pharmacological study (OTHER), terameprocol (DRUG).

Who is sponsoring clinical trial NCT00404248?

This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00404248 being conducted?

This trial has 9 study locations across Alabama, Florida, Georgia, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Brain and Central Nervous System Tumors

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Brain and Central Nervous System Tumors

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.